title: Prognostic factors and clinical outcomes of high-dose chemotherapy followed by autologous stem cell transplantation in patients with peripheral T cell lymphoma, unspecified: complete remission at transplantation and the prognostic index of peripheral T cell lymphoma are the major factors predictive of outcome.
abstract: High-dose chemotherapy followed by autologous stem cell transplantation (HDT/ASCT) offers a rescue option for T cell lymphoma patients with poor prognosis. However, the effectiveness of HDT/ASCT in patients with various peripheral T cell subtypes, optimal transplant timing, and the prognostic factors that predict better outcomes, have not been identified. We retrospectively investigated the clinical outcomes and prognostic factors for HDT/ASCT in 64 Korean patients with peripheral T cell lymphoma, unspecified (PTCL-U) between March 1995 and February 2007. The median age at transplantation was 44 years (range: 15-63 years). According to the age-adjusted International Prognostic Index (a-IPI) and the prognostic index of PTCL (PIT), 8 patients (12.5%) were in the high-risk group and 16 (26.6%) had the 2-3 PIT factors, respectively. After a median follow-up of 29.7 months, the 3-year overall survival (OS) and progression-free survival (PFS) rates were 53.0% +/- 7.5% and 44.3% +/- 7.0%, respectively. Univariate analysis showed that poor performance status, high lactate dehydrogenase (LDH) levels, high a-IPI score, high PIT classes, failure to achieve complete response (CR) at transplantation, and nonfrontline transplantation were associated with poor OS. Multivariate analysis showed that failure to achieve CR at transplantation (hazard ratio [HR] 2.23; 95% confidence interval [CI] 1.78-7.93) and 2-3 PIT factors (HR 3.76; 95% CI 1.02-5.42) were independent prognostic factors for OS. Failure to achieve CR at transplantation and high PIT are negative predictable factors for survival following HDT/ASCT in patients with PTCL-U.
authors.affiliation: Chonnam National University Hwasun Hospital, Jeollanam-do, Korea.
authors.forename: Deok-Hwan
authors.initials: DH
authors.lastname: Yang
authors.forename: Won Seog
authors.initials: WS
authors.lastname: Kim
authors.forename: Seok Jin
authors.initials: SJ
authors.lastname: Kim
authors.forename: Sung Hwa
authors.initials: SH
authors.lastname: Bae
authors.forename: Sung Hyun
authors.initials: SH
authors.lastname: Kim
authors.forename: In Ho
authors.initials: IH
authors.lastname: Kim
authors.forename: Sung Soo
authors.initials: SS
authors.lastname: Yoon
authors.forename: Yeung-Chul
authors.initials: YC
authors.lastname: Mun
authors.forename: Ho-Jin
authors.initials: HJ
authors.lastname: Shin
authors.forename: Yee Soo
authors.initials: YS
authors.lastname: Chae
authors.forename: Jae-Yong
authors.initials: JY
authors.lastname: Kwak
authors.forename: Hawk
authors.initials: H
authors.lastname: Kim
authors.forename: Min Kyoung
authors.initials: MK
authors.lastname: Kim
authors.forename: Jin Seok
authors.initials: JS
authors.lastname: Kim
authors.forename: Jong Ho
authors.initials: JH
authors.lastname: Won
authors.forename: Je-Jung
authors.initials: JJ
authors.lastname: Lee
authors.forename: Cheol Won
authors.initials: CW
authors.lastname: Suh
mesh_terms: D000293:Adolescent; D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D044466:Asian People; D018380:Hematopoietic Stem Cell Transplantation / Q000379:methods* / Q000401:mortality; D006801:Humans; D016411:Lymphoma, T-Cell, Peripheral / Q000401:mortality / Q000628:therapy*; D008875:Middle Aged; D011379:Prognosis; D012189:Retrospective Studies; D016019:Survival Analysis; D014182:Transplantation, Autologous; D016896:Treatment Outcome